Objective: This study aimed to evaluate the change in the patient's background and attitude toward infertility treatment both before and after the initiation of insurance coverage and to explore future issues from the patients' perspectives.

Materials And Methods: A cross-sectional survey was conducted in a fertility clinic in Japan from February to June 2022. An original questionnaire was given for two groups of new patients at a fertility clinic on their first visit: before fertility treatment insurance coverage started (Before-coverage) and after fertility treatment insurance coverage started (After-coverage).

Results: The study included 75 patients (Before-coverage = 25; After-coverage = 50). Multivariate analysis revealed increases among patients who consider infertility a "disease" rather than a "condition" (odds ratio (OR): 5.03, p < 0.05), those preferring in vitro fertilization (IVF) as an initial treatment (OR: 2.54, p = 0.03), and those who recommend oocyte freezing for one's child (OR: 3.88, p = 0.04), with statistical significance in the After-coverage group compared with the Before-coverage group. However, the anticipated financial burden did not change significantly (e.g., cost per IVF, cost to achieve pregnancy).

Conclusions: More patients had an impression of infertility as a "disease" and preferred IVF as the first treatment option after coverage than before coverage. Furthermore, many patients wanted to recommend oocyte freezing for their children despite the lack of insurance coverage. However, patients' anticipated economic burden for treatment was not different between both groups. The economic burden anticipated by patients remained unchanged, revealing the challenge of disseminating information to patients in the future.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669821PMC
http://dx.doi.org/10.7759/cureus.74459DOI Listing

Publication Analysis

Top Keywords

insurance coverage
20
fertility treatment
12
coverage
8
fertility clinic
8
treatment insurance
8
coverage started
8
infertility "disease"
8
recommend oocyte
8
oocyte freezing
8
economic burden
8

Similar Publications

Background: The benefits and cost-effectiveness of functional septorhinoplasty have been previously demonstrated. However, reimbursement for functional septorhinoplasty by health insurance companies remains inconsistent. The purpose of this study is to define the current state of insurance coverage for functional septorhinoplasty.

View Article and Find Full Text PDF

Background: /purposeSince 1995, Taiwan's National Health Insurance (NHI) has offered a comprehensive dental coverage to over 99 % of the population. This study mainly analyzed the dental service utilization and expenditure trends by the gender, age, and service type and evaluated the resource allocation across different demographics from 2000 to 2020.

Materials And Methods: Nationwide NHI administrative data were used to assess the dental visit rates, average visits per user, and per capita expenditure by the gender, age, and 11 service categories for the years 2000, 2005, 2010, 2015, and 2020.

View Article and Find Full Text PDF

Oral corticosteroids (OCS) are frequently used during pregnancy, but patterns of their usage and indications are understudied. We described OCS utilization among pregnant women in South Korea using the Health Insurance Review and Assessment database, 2010-2021. Among 4,574,294 pregnancies, 6.

View Article and Find Full Text PDF

Objectives: The US Preventive Services Task Force recommends screening of adults aged 35-70 with a body mass index ≥25 kg/m for type 2 diabetes and referral of individuals who screen positive for pre-diabetes to evidence-based prevention strategies. The diabetes burden in the USA is predicted to triple by 2060 necessitating strategic diabetes prevention efforts, particularly in areas of highest need. This study aimed to identify pre-diabetes hotspots using geospatial mapping to inform targeted diabetes prevention strategies.

View Article and Find Full Text PDF

Comparison of Oncology Drug Lag in Japan and South Korea Based on the Interval between the U.S. Approval and the Local Approval.

Biol Pharm Bull

January 2025

Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.

Drug lag is a serious issue for patients with life-threatening diseases such as cancer. Japan and Korea have been facing a large drug lag, despite having a large market and a good clinical trial environment. We analyzed drug lags for anticancer drugs between these countries, using the information on 82 anticancer drugs approved in the United States between 2017 and 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!